multiple myeloma
Conditions
Interventions
Case series:Huachansu, 4 tablets (1.2g) orally, tid
Control group:Bortezomib combined with TD scheme
Sponsors
Affiliated Hospital of Nanjing University of Chinese Medicine (JiangSu Province Hospital of TCM)
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed diagnosis of multiple myeloma; 2. Aged between 40 ~ 80 years old, gender is not limited; 3. Informed consent, voluntary testing.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating patients; 2. Allergy, such as two or more drugs or food allergy history; or known to the drug allergy; 3. Uncontrolled positive infection, including but not limited to hepatitis B, hepatitis C, syphilis, AIDS positive and active; 4. Hypovolemia or hypotension, severe valvular stenosis, arteriovenous shunt in patients; patients with severe angina pectoris; Heart failure with malignant arrhythmias. Severe liver dysfunction patients (ALT, AST> 1.5 times the upper limit of normal); 5. Psychotic patients; 6. Participate in other clinical trials; 7. Suspected or indeed alcohol, drug abuse history; 8. Patients with poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bone marrow plasma cells;immunoglobulins;immune fixation electrophoresis;Flow cytometry;blood and urinary light-chain;ß2-MG; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum albumin;blood routine; | — |
Countries
China
Contacts
Public ContactXuejun Zhu
Department of Hematology, Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of TCM)
Outcome results
None listed